Royalty Pharma
RPRX
448 hedge funds and large institutions have $10.1B invested in Royalty Pharma in 2025 Q1 according to their latest regulatory filings, with 84 funds opening new positions, 160 increasing their positions, 150 reducing their positions, and 51 closing their positions.
160% more call options, than puts
Call options by funds: $89M | Put options by funds: $34.2M
65% more first-time investments, than exits
New positions opened: 84 | Existing positions closed: 51
7% more funds holding
Funds holding: 418 → 448 (+30)
2.07% more ownership
Funds ownership: 72.43% → 74.49% (+2.1%)
7% more repeat investments, than reductions
Existing positions increased: 160 | Existing positions reduced: 150
6% more capital inflows, than outflows
Capital inflows: $1.25B | Capital outflows: $1.18B
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$413M |
| 2 |
Caledonia Investments (Australia)
Sydney NSW,
Australia
|
+$162M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
+$83.8M |
| 4 |
Morgan Stanley
New York
|
+$47.5M |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
+$33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$340M |
| 2 |
Millennium Management
New York
|
-$66.8M |
| 3 |
SGA
Siguler Guff Advisers
New York
|
-$60.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$56.3M |
| 5 |
Viking Global Investors
Stamford,
Connecticut
|
-$52.1M |
RPRX Hedge Fund Activity: Q1 2025 in Review
448 of the 7,478 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q1 2025, worth a combined $10.1B — up 22% from $8.21B a quarter earlier.
Buyers outnumbered sellers: 84 funds opened new RPRX positions and 51 closed out — a net gain of 33 holders — while 160 added to existing stakes and 150 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $413M. The largest seller was Adage Capital Partners, cutting an estimated $340M.
- 448 institutional investors held Royalty Pharma (RPRX) as of Q1 2025, up from 418 in Q4 2024.
- Funds reported $10.1B of Royalty Pharma stock for Q1 2025, up 22% quarter-over-quarter.
- 84 funds opened new Royalty Pharma positions in Q1 2025 and 51 closed out, a net change of +33 holders.
- The largest Royalty Pharma buyer in Q1 2025 was Fidelity Investments, an estimated $413M added.
- The largest Royalty Pharma seller in Q1 2025 was Adage Capital Partners, an estimated $340M sold.
Based on aggregated 13F filings for Q1 2025.